Purpose: To evaluate the anatomical and visual effects of biosimilars in the treatment of wet age-related macular degeneration (AMD). Methods: We retrospectively reviewed patients with wet AMD treated with originator or biosimilar ranibizumab (CKD-701) or aflibercept (SB15) between June 2024 and February 2025 at Severance Eye Hospital. Clinical outcomes were assessed over six months using best corrected visual acuity (BCVA) and central macular thickness (CMT) measurements. Results: Among 272 patients, 91 received ranibizumab (54.9% originator, 45.1% biosimilar) and 181 received aflibercept (66.9% originator, 33.1% biosimilar). In the ranibizumab group, BCVA and CMT improvements were comparable between originator and biosimilar formulations, with no significant differences in injection number. In the aflibercept group, the biosimilar cohort received significantly fewer injections (3.63 [originator] vs. 3.11 [biosimilar], p = 0.006) and showed slightly inferior visual and anatomical outcomes, likely influenced by a smaller proportion of treatment-naïve patients and limited insurance coverage. No serious adverse events were observed in any group. Conclusions Biosimilars demonstrated acceptable efficacy and safety over six months. Broader use could improve accessibility, though further long-term data are needed.

PURPOSE: To report a case of isolated conjunctival lymphangioma mimicking a recurrent conjunctival cyst. CASE SUMMARY: A 39-year-old male with a conjunctival cyst in the right eye lasted for 1 month visited our hospital. He had previously undergone aspiration of the cyst at another hospital 1 week before visiting our hospital. However, the cyst recurred, and he was referred to our hospital. On slit lamp biomicroscopy, yellow-colored turbid fluid and a hemorrhage were observed in the conjunctival cyst, but no specific finding was found in the fundus photography. The patient was initially treated with topical antibiotics and steroids. Three weeks later, absorption of the hemorrhage was noted, but there was no change in the size of the cyst. Therefore, surgical removal and histological examination of the cyst were performed. The histological examination revealed that the lesion was positive for CD 31 and D2-40, and the cyst was diagnosed as a cystic conjunctival lymphangioma. Thereafter, brain magnetic resonance imaging was performed to screen for orbital lymphangioma and systemic disease that could accompany a conjunctival lymphangioma. However, no specific findings were observed. There was no recurrence of the conjunctival cyst at 1 year and 6 months after surgical removal, and no other ophthalmic or systemic complication was observed. CONCLUSIONS: An isolated conjunctival lymphangioma is a rare lesion. In the diagnosis of lymphangioma, systemic examination is recommended for the identification of comorbid diseases, such as orbital lymphangioma.
Absorption ; Adult ; Anti-Bacterial Agents ; Brain ; Diagnosis ; Hemorrhage ; Humans ; Lymphangioma ; Magnetic Resonance Imaging ; Male ; Orbit ; Photography ; Recurrence ; Slit Lamp ; Steroids